Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009

Occupational and Environmental Medicine

Volumn 73, Issue 3, 2016, Pages 187-194

  Soeberg, Matthew J ^a,b   Leigh, James ^b   Driscoll, Tim ^a   Armstrong, Bruce ^a   Young, Jane M ^a   Van Zandwijk, Nico ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

^c CANCER INSTITUTE NSW   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AUSTRALIA; CANCER INCIDENCE; CANCER SURVIVAL; CHILD; FEMALE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MORTALITY; NEWBORN; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SURVIVAL; CASE CONTROL STUDY; ENVIRONMENTAL EXPOSURE; INCIDENCE; LUNG; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PERITONEUM; PLEURAL NEOPLASMS; PRESCHOOL CHILD; YOUNG ADULT;

ASBESTOS; CARCINOGEN;

ADOLESCENT; ADULT; AGED; ASBESTOS; AUSTRALIA; CARCINOGENS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LUNG; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PERITONEUM; PLEURAL NEOPLASMS; YOUNG ADULT;

EID: 84958697147     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oemed-2015-103309     Document Type: Review

References (40)

1. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 2013;34:205-16.
2. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17.
3. Australian Mesothelioma Registry. Mesothelioma in Australia 2013. Sydney, Australia: Australian Mesothelioma Registry, 2014.
4. Leigh J, Corvalan CF, Grimwood A, et al. The incidence of malignant mesothelioma in Australia 1982-1988. Am J Ind Med 1991;20:643-55.
5. Bray F, Moller B. Predicting the future burden of cancer. Nat Rev Cancer 2006;6:63-74.
6. Leigh J, Hull B, Davidson P. Malignant mesothelioma in Australia (1945-1995). Ann Occup Hyg 1997;41:161-7.
7. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books: mesothelioma. Canberra, Australia, 2015.
8. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 2009;20:935-44.
9. Australian Institute of Health and Welfare (AIHW). Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Cancer Series no. 69. Cat. no. CAN 65, Canberra, Australia: Australian Institute of Health and Weflare, 2012.
10. Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med 2004;23:51-64.
11. Yu XQ, O'Connell DL, Gibberd RW, et al. Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia. Int J Cancer 2006;119:894-900.
12. Davidson B. Prognostic factors in malignant pleural mesothelioma. Hum Pathol 2015;46:789-804.
13. Linton A, Pavlakis N, O'Connell R, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014;111:1860-9.
14. Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159-65.
15. Australian Bureau of Statistics. 3222.0 Population Projections. Australia, 2013.
16. Sasieni P. Age-period-cohort models in Stata. Stata J 2012;21:45-60.
17. Moller B, Fekjaer H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003;22:2751-66.
18. Moller B, Fekjaer H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev 2002;11(Suppl 1):S1-96.
19. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996;78:2004-10.
20. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101-21.
21. Dickman PW, Coviello E. Estimating and modeling relative survival. Stata J 2015;15:186-215.
22. Champion de Crespigny FE, Macfarlane E, Laws P, et al. Mesothelioma in Australia -monitoring disease incidence and past asbestos exposure with the Australian Mesothelioma Registry. Asian Pac Newsl Occup Health Saf 2014;21:24-7.
23. Leigh J, Davidson P, Hendrie L, et al. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002;41:188-201.
24. Olsen NJ, Franklin PJ, Reid A, et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 2011;195:271-4.
25. Park EK, Yates DH, Hyland RA, et al. Asbestos exposure during home renovation in New South Wales. Med J Aust 2013;199:410-13.
26. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007;45:379-87.
27. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-21.
28. Linton A, Vardy J, Clarke S, et al. The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol 2012;84:200-12.
29. Marinaccio A, Binazzi A, Cauzillo G, et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007;43:2722-8.
30. Reid A, de Klerk NH, Magnani C, et al. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax 2014;69:843-50.
31. van Zandwijk N. Clinical practice guidelines for malignant pleural mesothelioma. J Thorac Dis 2013;5:724-5.
32. Cao C, Yan TD, Deraco M, et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494-8.
33. Mirarabshahii P, Pillai K, Chua TC, et al. Diffuse malignant peritoneal mesothelioma -an update on treatment. Cancer Treat Rev 2012;38:605-12.
34. van Meerbeeck JP, Scherpereel A, Surmont VF, et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol 2011;78:92-111.
35. Krupoves A, Camus M, De Guire L. Incidence of malignant mesothelioma of the pleura in Quebec and Canada from 1984 to 2007, and projections from 2008 to 2032. Am J Ind Med 2015;58:473-82.
36. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107-12.
37. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93.
38. Marinaccio A, Binazzi A, Marzio DD, et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer 2012;130:2146-54.
39. Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185-9.
40. Organising Committee. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Sydney, Australia: Asbestos Diseases Research Institute, 2013.